Patents by Inventor Steven Witowski

Steven Witowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
    Publication number: 20230310329
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: April 14, 2023
    Publication date: October 5, 2023
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
    Publication number: 20220125734
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: January 7, 2022
    Publication date: April 28, 2022
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
    Publication number: 20210290554
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: June 2, 2021
    Publication date: September 23, 2021
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
    Publication number: 20190029967
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 31, 2019
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
    Publication number: 20150132375
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: January 15, 2015
    Publication date: May 14, 2015
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Orally Disintegrating Compositions of Linaclotide
    Publication number: 20150031632
    Abstract: The present invention relates to orally disintegrating or dissolving pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 29, 2015
    Inventors: YUN MO, MAHENDRA DEDHIYA, ANIL CHHETTRY, ANGELIKA FRETZEN, STEVEN WITOWSKI, ALFREDO GROSSI, HONG ZHAO
  • Treatment of Chronic Constipation
    Publication number: 20140349948
    Abstract: The invention provides methods for treating a patient with chronic constipation by administering a therapeutically effective dose of linaclotide.
    Type: Application
    Filed: December 23, 2013
    Publication date: November 27, 2014
    Applicants: Forest Laboratories Holdings Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Jeffrey Johnston, Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Bernard Joseph Lavins, Mahendra Dedhiya, Harvey Schneier
  • Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
    Publication number: 20140287034
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: May 23, 2014
    Publication date: September 25, 2014
    Applicants: Ironwood Pharmaceuticals, Inc., Forest Laboratories Holdings Limited
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration
    Patent number: 8802628
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: August 12, 2014
    Assignees: Ironwood Pharmaceuticals, Inc., Forest Laboratories Holdings, Ltd.
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Formulations comprising linaclotide
    Patent number: 8748573
    Abstract: The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: June 10, 2014
    Assignee: Ironwood Pharmaceuticals, Inc.
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
    Publication number: 20130273169
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Linaclotide for the Treatment of Chronic Constipation
    Publication number: 20130059797
    Abstract: The invention provides methods for treating a patient with chronic constipation by administering a therapeutically effective dose of linaclotide.
    Type: Application
    Filed: November 3, 2010
    Publication date: March 7, 2013
    Applicants: Forest Laboratories Holdings Limited, Ironwood Pharmaceuticals ,Inc.
    Inventors: Jeffrey Johnston, Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Bernard Joseph Lavins, Mahendra Dedhiya, Harvey Schneier
  • Orally Disintegrating Compositions of Linaclotide
    Publication number: 20130012454
    Abstract: The present invention relates to orally disintegrating or dissolving pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well to various methods and processes for the preparation and use of the compositions.
    Type: Application
    Filed: August 11, 2010
    Publication date: January 10, 2013
    Applicants: Ironwood Pharmaceuticals, Inc., Forest Laboratories Holdings Limited
    Inventors: Yun Mo, Mahendra Dedhiya, Anil Chhettry, Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao
  • Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
    Publication number: 20120213846
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: August 14, 2009
    Publication date: August 23, 2012
    Applicants: Forest Laboratories Holdings Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
    Publication number: 20120039949
    Abstract: Solid, stable formulations of GC-C receptor agonist polypeptide suitable for oral administration are described herein as are methods for preparing such formulations. The GC-C receptor agonist polypeptide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: August 14, 2009
    Publication date: February 16, 2012
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao
  • Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
    Publication number: 20120009225
    Abstract: Solid, stable formulations of therapeutic polypeptide suitable for oral administration are described herein as are methods for preparing such formulations. The therapeutic polypeptide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: August 14, 2009
    Publication date: January 12, 2012
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao
  • Formulations Comprising Linaclotide
    Publication number: 20110059903
    Abstract: The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.
    Type: Application
    Filed: August 5, 2010
    Publication date: March 10, 2011
    Applicants: Ironwood Pharmaceuticals, Inc., Forest Laboratories Holdings Limited
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Stable Solid Formulation of A GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
    Publication number: 20100048489
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: August 14, 2009
    Publication date: February 25, 2010
    Applicant: Ironwood Pharmaceuticals Inc.
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo